A unified framework to explain one of cancer's major drivers
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
In a rare pair of papers published back-to-back in the journal Genes & Development, research teams led by senior author Anindya Bagchi, Ph.D., associate professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys Medical Discovery Institute, establish a unified framework that governs one of cancer's most powerful master regulators.
The MYC gene is among the most frequently altered driver genes in human cancer, with its deregulation implicated in more than half of all cases. It acts as a master regulator controlling cell growth, division and metabolism.
When overactive, MYC forces cells into rapid, uncontrolled tumor growth and drives aggressive, treatment-resistant cancers across virtually all tumor types, from solid tumors like breast and lung to blood cancers like leukemia.
Historically, MYC has been considered "undruggable" because the MYC protein lacks the typical binding pockets targeted by traditional small-molecule drugs, leaving clinicians with few direct ways to shut down MYC‑driven tumors.
"These paired, back-to-back publications tell a remarkable story about untangling a long-standing mystery in cancer biology, a mystery I tried to solve as part of my own Ph.D. two decades ago," said Paul Boutros, Ph.D., MBA, director of the National Cancer Institute-designated cancer center at Sanford Burnham Prebys. "It's an incredible achievement by Bagchi, and really reflects the caliber and impact of discovery science that defines our cancer center."
PVT1 emerges as control hub
The new studies focus on a region adjacent to MYC on human chromosome 8q24, known as the Plasmocytoma Variant Translocation 1 (PVT1) locus. Previous work in the Bagchi lab had shown that PVT1 is essential for MYC-driven tumor growth, but the mechanism was unknown.
The paired papers solve this puzzle with an unexpected answer: PVT1 is an active regulatory hub for MYC activity, encoding two novel proteins that play key roles in enabling MYC in these cancers.
"These two studies show that you do not have to hit MYC directly to control MYC‑driven cancers," Bagchi said. "By uncovering key molecules that MYC depends on, we are opening up a new set of therapeutic entry points for tumors that have long been considered beyond the reach of targeted therapies."
Firefox helps sustain MYC
In the first paper, Bagchi and colleagues focused on PVT1, until now considered a long noncoding RNA adjacent to MYC and frequently co-amplified with MYC in many cancers.
Previous research had shown PVT1 increases MYC activity, but the new study revealed that PVT1 does so by generating a circular RNA (CircPVT1) that encodes a novel protein the researchers named Firefox. They determined that Firefox is essential for MYC-mediated oncogenic signaling—the cascade of molecular events that drive the uncontrolled growth, survival and spread of cancer cells.
When researchers depleted Firefox, MYC protein abundance and transcriptional output declined. In animal models of MYC-driven cancers, induced depletion of Firefox significantly impaired tumor growth.
"Firefox behaves like a critical helper that MYC needs in order to fully transform a cell into a cancer cell," Bagchi said. "If you remove Firefox, MYC loses much of its power, which makes Firefox a very attractive potential drug target in MYC‑driven tumors."
Honeybadger removes a brake
In the second paper, Bagchi and colleagues examined a second kind of structural rearrangement at PVT1 and discovered that a segment of PVT1 is consistently deleted due to translocation.
A translocation occurs when a segment of DNA breaks away from one chromosome and attaches to a different chromosome.
The researchers found that the affected segment encodes a novel micropeptide, which they dubbed Honeybadger. The micropeptide, they said, acts as a built-in brake on cancer growth.
Honeybadger directly binds KRAS—a key signaling protein in cancer. Mutated forms of KRAS are major drivers of tumor growth and are implicated in roughly 25% to 30% of all human cancers.
By binding KRAS, Honeybadger dampens the RAS‑MAPK signaling pathway under normal conditions. When PVT1 translocations delete the Honeybadger-encoding region, the brake is removed, allowing wild-type KRAS to hyperactivate MAPK signaling.
This in turn stabilizes MYC protein and amplifies its cancer-driving output—even in tumors that lack KRAS mutations. The result is a dual hit: gain of the Firefox oncoprotein and loss of the Honeybadger tumor suppressor, which synergistically boosts MYC output and helps explain the particularly poor prognosis of PVT1‑rearranged cancers.
"The surprising lesson from these two papers is that PVT1 is not just a passive neighbor of MYC. It is an active regulatory hub that can either fuel or restrain MYC‑driven cancers, depending on which of its products are present," Bagchi said.
"Together, the papers establish a 'dual-hit' mechanism: a single structural alteration at PVT1 simultaneously preserves an oncogene (Firefox) and eliminates a tumor suppressor (Honeybadger), with both changes converging to amplify MYC activity. This makes PVT1 and its encoded proteins an especially rich source of new biomarkers and potential therapeutic targets."
From mechanism to drug leads
Bagchi said the research team next plans to investigate how Firefox and Honeybadger behave in additional cancer types and to work with collaborators to begin developing prototype therapeutic strategies.
"Our goal is to translate these basic discoveries into first‑in‑class therapeutic approaches that could ultimately benefit patients with MYC‑driven tumors, which currently have very limited targeted treatment options," he said.
Publication details
Ashutosh Tiwari et al, Firefox, a protein encoded by circular PVT1 , is essential for MYC-driven oncogenesis, Genes & Development (2026). DOI: 10.1101/gad.353355.125
Utkarsha Paithane et al, Honeybadger, a micropeptide encoded by an alternative PVT1 transcript, is a critical negative regulator of RAS–MAPK signaling in MYC-driven tumors, Genes & Development (2026). DOI: 10.1101/gad.353356.125
Journal information: Genes & Development
Clinical categories
OncologyClinical genetics Provided by Sanford-Burnham Prebys Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: A unified framework to explain one of cancer's major drivers (2026, August 20) retrieved 20 August 2026 from https://medicalxpress.com/news/2026-08-framework-cancer-major-drivers.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.